Lowest vs highest tertile of total hip BMD was significantly associated with a 2.2-fold increased risk for major adverse cardiovascular events, study finds.
Higher risk persisted after adjustment for broad range of clinical, anthropometric, and lifestyle risk factors
Apixaban the only direct oral anticoagulant linked to lower adverse event rates than warfarin for patients with atrial fibrillation across frailty levels
A team of UK-based investigators explored the long-term cardiovascular outcomes in patients with obesity who were administered orlistat therapy.
Each 1 mg/dL rise in uric acid level was significantly associated with a 21% and 10% increased risk for cardiovascular and all-cause mortality, respectively, a study found.
Risk for adverse events attributable to statins low when used for primary prevention of cardiovascular disease
In contrast, much higher event rate seen for racial and ethnic minorities randomly assigned to drug therapy in CABANA trial
The FDA conducted a comprehensive review of all available data associated with the use of statins during pregnancy.
Dapagliflozin’s benefits among patients with stage 4 CKD were consistent with those observed in the larger DAPA-CKD cohort with stage 2-3 CKD.
In a small study, approximately a third of kidney transplant recipients had anemia and half had persistent secondary hyperparathyroidism.